18F-FDG PET/CT assess tumor response in Chinese patients with relapsed/refractory classical Hodgkin lymphoma treated by novel Programmed Death-1 (PD-1) Inhibitors, Tislelizumab or Camrelizumab

Conclusions: Tislelizumab or Camrelizumab could be a new treatment option for patients with relapsed or refractory classical Hodgkin lymphoma in China. Three-month 18F-FDG PET/CT scans detected HL patients responding to anti-PD1. New patterns were encountered in 15% of patients, emphasizing the need for further evaluation in larger series and close collaboration between imaging and oncology specialists on a per-patient basis.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lymphoma / Leukemia / Myeloma Posters Source Type: research